A phase II, multi-center, open-label trial to evaluate the efficacy and safety of intravenous DAVANAT in combination with 5-fluorouracil when administered in monthly cycles as third- or fourth-line therapy for metastatic colorectal cancer.
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2012
At a glance
- Drugs Fluorouracil; Galactomannan C
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Mar 2012 Company (Galectin Therapeutics) added as trial sponsor as reported by ClinicalTrials.gov.
- 05 Mar 2012 Planned end date 1 Feb 2008 added added as reported by ClinicalTrials.gov.